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• 60 yo male with hypertension
• Aortic dissection in early 2013
•

Repair with aortic graft

• Well until late 2014:
•
•

Weight loss (60 lbs total)
Fatigue, fevers, & night sweats

• Massive hepatosplenomegaly
•  LFTs, pancytopenia

AFB Blood Culture Turns +

DNA probe + for Mycobacterium avium complex (MAC)
Molecular ID eventually reveals: M. chimaera
Tortoli. Clin Micro Rev 2014;27:727.

Mycobacterium avium Complex (MAC)
• Slow-growing, ubiquitous in environment
– Surface water, tap water, and soil

• Low virulence, opportunistic pathogens
– Disseminated disease described with extreme
immune compromise (AIDS)
– Chronic lung disease, airway abnormalities

• Detection challenging (2-8 weeks to grow)
How did this otherwise healthy patient
acquire disseminated MAC disease?

•
•
•
•

Invasive M. chimaera infection in 6 patients
All the case patients had cardiac implants
Time from surgery to diagnosis: 1.7-3.6 years
Investigation of water sources revealed:
– Water in heater-cooler devices grew M chimaera
• LivaNova (formerly Sorin) Stockert 3T

– Air samples grew the outbreak strain when units ran
– Water, air and patient samples matched by RAPD-PCR
Clin Infect Dis 2015 (July 1);61:67

What is a Heater-Cooler Device (HCD), and how
could it serve as a source of bio-aerosols?

Clin Infect Dis 2015 (July 1);61:67

Although water from heater-cooler
never contacts patients directly, the
circuit is not airtight (or watertight), so
the ventilation fan can aerosolize
contaminated water from the circuit

Peeking under the hood…

Chand et al. Clin Infect Dis 2017;64:335-42.
Lyman, et al. Emerg Infect Dis 2017;23:796.

Walker, et al. J Hosp Infect 2017;96:209-220.

Walker, et al. J Hosp Infect 2017;96:209-220.

Contamination of the operative field
HCU fan facing away from operative field

HCU fan facing operative field

Sommerstein R, et al. EID 2016;22:1008-1013
https://www.youtube.com/watch?v=YZ41aLoHrhQ

Outbreak investigation at Wellspan York:
CDC and Pennsylvania DOH
• Case control study performed
– 11 cases, 48 controls
– Cases: extra-pulmonary NTM up to 3.5 years after
cardiothoracic surgical procedure
– Controls: no + cx after CT surgery

• Exposure to HCD was a risk factor
• Exposure > 2 hrs to HCD (OR = 16.5 [3.2-84])
• Molecular typing linked patient isolates
Lyman, et al. Emerg Infect Dis 2017;23:796.

Why Mycobacterium chimaera?
1. Because LivaNova 3Ts may have arrived
already contaminated with M. chimaera
2. Because M. chimaera (and other NTM) are
perfectly suited to survive in, and aerosolize
from, water circuits

Evidence for Contamination at the Source

“HCDs….may have had environmental mycobacteria presence in the
unit at the time of delivery.”
Haller S et al. Eurosurveillance 2016;21:17.

Molecular epidemiology:
A common source outbreak
• Whole genome sequencing reveals isolates
from multiple continents to be closely related:
– 3T HCD and patient isolates from UK, Europe, US, AU/NZ
•
•
•
•

van Ingen J, et al. Lancet Infect Dis 2017 (ePub)
Svensson E, et al. Emerg Infect Dis 2017;23:507-509.
Perkins KM, et al. MMWR 2016;65:1117-18
Williamson D, et al. N Engl J Med 2017;376:600-602

“We find it likely that most [LivaNova] Sorin 3T
HCDs made in the past 8-10 years potentially are
contaminated by the same M. chimaera strain”

WGS of 250 isolates worldwide

Group 1: median 20 SNP diff
Group 1.1: median 4 SNP diff
Outbreak pts, HCD water/air
Factory units and water

“HCD contamination with M. chimaera at the LivaNova factory seems
a likely source for…surgery-related severe M. chimaera infections ”
– van Ingen, et al. Lancet Infect Dis 2017 July 12 (ePub)

Global outbreak of HCD-associated M. chimaera
•
•
•
•
•
•
•
•
•

Switzerland
Germany
France
Spain
Netherlands
United Kingdom
Hong Kong
Australia
Canada

Worldwide case count unknown, >110

M. chimaera aerosolization in the OR:
Pathogenesis of disseminated infection
• Most patients to date with disseminated infections
have implants (valves, vascular grafts, LVADs)
• High inoculum (long bypass time, direction of
exhaust, OR air handling) results in contamination of
implant, leads to biofilm formation on an
intravascular device
• Chronic granulomatous inflammatory response to
near-continuous bacteremia with a low virulence
organism that is otherwise easily contained

MAC Outer Membrane Favors
Persistence in Water Systems
• Lipid-rich hydrophobic barrier
• Resistant to common disinfectants
– Chlorine, chloramine, ozone

• 1,000 times more resistant than industry
standard for disinfection (E. coli)
– 5 seconds vs. 2 hours at 1 ppm chlorine

• Form thick biofilms, enhance resistance
– 10,000 CFU/cm2 in biofilm
Taylor, et al. Appl Environ Microbiol 2000;66:1702-5.
Steed, et a. Appl Environ Microbiol 2006:72:4007.

MAC Hydrophobicity:
Role in Aerosolization
• Concentrate on surface of air
bubbles in water columns
• Aerosolization as bubbles reach
surface
• MAC concentration in ejected
droplets is 1,000-10,000 X
higher than in water
Parker, et al. Am Rev Respir Dis 1983;128:652-56.

Clinical manifestations
• Surgical wound infection
– SSI, sternal osteomyelitis, mediastinitis, abscess

•
•
•
•

Prosthetic valve endocarditis
Vascular graft infection
LVAD infection
Dissemination:
–
–
–
–
–
–
–
–

Bone marrow (cytopenias common)
Splenomegaly
Hepatitis
Nephritis
Arthritis and osteomyelitis (spine, discitis)
Chorioretinitis
Pneumonitis
Myocarditis

Disseminated M. chimaera: Device Associated

Current approach to therapy includes multiple drug treatment
(macrolide, ethambutol, rifamycin, +/- amikacin, +/- moxifloxacin) ,
and removal of involved devices (valve, graft) if possible.
Kohler, et al. Eur Heart J 2015;36:2745

M. chimaera clinical experience
52 cases from 3 case series (US, UK, EU)
Patient Characteristics

Results

Total number of cases

52

Earliest sentinel surgery

2008

Male

83%

Age, y (mean, range)

60 (1-83)

Prosthetic cardiovascular material
Duration from surgery to symptom onset in months, mean (range)
Crude mortality at time of publication or presentation of cases

90%
17 (1-72)
48%

Appenheimer AB et al. IDWeek 2016, #2392, October 29, 2016.
Chand M, et al. Clin Infect Dis 2017;64:335-42.
Kohler P, et al. European Heart Journal 2015;36:2745-53.

Surgical procedure
Prosthetic Valve/Ring
Aortic graft
LVAD
Valve + graft
Heart transplant
Localized, sternal wound/mediastinitis/pleural
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Appenheimer AB et al. IDWeek 2016, #2392, October 29, 2016.
Chand M, et al. Clin Infect Dis 2017;64:335-42.
Kohler P, et al. European Heart Journal 2015;36:2745-53.

Clinical presentation

Symptoms

%

Fatigue

90

Presumed source

N

Fever

75

Prosthetic valve

32

Sweats

60

Aortic graft

9

Dyspnea

60

LVAD

6

Weight loss

60

Sternal wound

5

Cough

50

• Sites of dissemination: liver, spleen, bone marrow,
kidney, eye (chorioretinitis), spine (osteomyelitis), joints,
pleural space, psoas muscle, myocardium
• Histopathology: non-caseating granulomas, rarely AFB
smear positive
Appenheimer AB et al. IDWeek 2016, #2392, October 29, 2016.
Chand M, et al. Clin Infect Dis 2017;64:335-42.
Kohler P, et al. European Heart Journal 2015;36:2745-53.

Diagnosis (2 case series, 34 patients)
Sites of positive culture

N

Blood

14

Bone marrow

5

Cardiac tissue or device

5

Sternal wound

3

Pleural space

3

Liver

2

Urine

2

LVAD pocket

1

• PCR can be valuable in setting of negative cultures
• 7 of 10 cardiac tissue PCR + in Kohler series
Appenheimer AB et al. IDWeek 2016, #2392, October 29, 2016.
Kohler P, et al. European Heart Journal 2015;36:2745-53.

Diagnostic considerations
• If exposed and with unexplained symptoms:
– Fatigue, fever, night sweats, weight loss, surgical site
– Exam: ? HSM, surgical site, joint involvement, ophtho exam
– Labs: CBC/diff, chem 7, LFTs, CRP, UA, AFB blood/other cx

• Cytopenias, elevated LFTs, AKI, chorioretinitis
– Often seen at presentation with disseminated disease

• Cultures require mycobacterial lab expertise
–
–
–
–

Take several weeks to turn positive
ID as “MAC” by probe, few labs can do species ID
Culture blood (>=2 sets) and any involved site
“Screening” AFB blood cultures (asymptomatic) not indicated

Outcomes of invasive M. chimaera
• Case series to date: crude mortality 50%
• Among the remaining 50%:
– Those with localized infections (e.g. sternal
wound, mediastinal abscess) cured with I&D
– Those with disseminated infection:
• Unwell, tenuous, on medical treatment
• In post surgical (device removal) monitoring period

– More experience, follow up needed (registry)
Appenheimer AB et al. IDWeek 2016, #2392, October 29, 2016.
Chand M, et al. Clin Infect Dis 2017;64:335-42.
Kohler P, et al. European Heart Journal 2015;36:2745-53.

Are your patients at risk?
• Yes, if LivaNova (Sorin) 3T HCDs used
anytime since….2008, 2010, 2012?
– Assume HCDs are contaminated regardless
of manufacture date or HCD culture results
– Next steps:
• Find current cases
1
2

• Manage identified cases

3

• Prevent additional cases

Case finding
Assemble a team to coordinate:
• Development of line list of those exposed
– Patient notification (closed loop, call-in line)
– Laboratory and EMR look-back
– EMR alert (exposed + febrile/other illness)

• Provider notification, Media release
• Patient evaluation: diagnostic approach
http://ecdc.europa.eu/en/publications/Publications/RRA-mycobacterium-chimaera-November-2016.pdf

https://www.cdc.gov/hai/outbreaks/heater-cooler.html
http://haicontroversies.blogspot.com/2016/11/the-m-chimaera-how-to-guide.html

Case finding
• Exposed patients with consistent syndrome:
– Offered evaluation in a dedicated NTM clinic
• Staffed by a physician’s assistant
• Directed by an ID physician
• Checklist developed with input from ID and external
experts to trigger the need for cultures
– Included symptoms, signs, lab results (elevated LFTs,
pancytopenia), prior workup

– Instructions provided for pts to take to local PCP

Case finding results: University of Iowa
• First case detected January 2016
• 1,500 patients potentially exposed
• ~150 symptomatic patients underwent
evaluation in “NTM clinic”
– no additional cases diagnosed from this clinic

• 6 M. chimaera cases identified to date

Case finding: Challenges
• Many pts receive follow-up care locally, not at the
center where they had surgery
• Symptoms are very nonspecific
– fever, fatigue, arthralgias/myalgias

• Long incubation period
• Mycobacterial cultures are not routinely
performed, but are required for diagnosis

Case finding: Challenges
• Mycobacteriology laboratory capacity
– Our initial evaluation exceeded capacity of blood
culture instrument, so we converted to manual
Isolator method temporarily
– For most labs, species-level ID (M. chimaera) and
susceptibility testing is a send out

• Discuss with lab director!

Prevention: The Swiss Cheese Model

Schrieber and Sax. Curr Opin Infect Dis 2017

Prevention measures:
HCD management
• Manufacturer cleaning/disinfection guidance
–

http://www.livanova.sorin.com/products/cardiac-surgery/perfusion/hlm/3t

• FDA and LivaNova recommend considering
environmental cultures to monitor HCD
–

http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm466963.htm

• Few labs have expertise in NTM isolation
– One center, same week, two labs  opposite results

• Negative predictive value is unknown
• Sequential testing demonstrates variability
• Safest to consider all 3T HCDs contaminated

Can M. chimaera be eradicated from HCDs?
• Contamination of new, factory-direct units quickly detected
• Multiple cycles of decontamination fail to eliminate:
–
–

Daily water changes with filtered water and 100 mL 3% H2O2
Biweekly disinfection with bleach or peracetic acid + H2O2

M. chimaera
Other NTM

Schreiber PW et al. Emerg Infect Dis 2016;22:1830-3.
Garvey MI et al. J Hosp Infection 2016;93:229-34.
Gotting T et al. J Hosp Infection 2016;93:223-8.

A year in the life of a contaminated HCU…

M. chimaera
Total CFU
Mold counts
P. aeruginosa

Garvey, et al. Infect Cont Hosp Epi 2017;38:705-711.

“Degradation and breakdown
of internal components”

Prevention measures:
Separation of HCD exhaust from OR air

Schreiber PW et al. Emerg Infect Dis 2016;22:1830-3.
Marra A, et al. Clin Infect Dis 2017 April 19 (ePub).

Prevention measures:
Separation of HCD exhaust from OR air

Walker, et al. J Hosp Infect 2017;96:209-220.

Prevention measures:
“Wall water” system that eliminates need for HCD
Utilizes hot and cold water inputs
and medical grade mixing valve to
carefully regulate water temperature
and delivery to the bypass system.
Built-in water filtration.
Watertight, no HCD, no fans.
Requires major capital investment
for hospitals without hot and cold
water supply in proximity to OR.
Matte GS, Sandora TJ, et al. SHEA Spring Meeting, 2017, St. Louis, MO.

Internal sealing
Vacuum system

Summary: Epidemiology
• Common source outbreak of M. chimaera
– LivaNova 3T HCDs contaminated at manufacturing facility
– Exposure to HCD exhaust air during surgery

• Extent of outbreak unknown at this time
– Very long incubation/discovery period (> 6 years)
– Clinical follow up often distant from exposure
– Risk: if case detected, risk 1/100 -1/1,000

• Risk from other HCDs, other organisms?

Summary: Clinical Manifestations
• Challenging clinical syndrome:
– Delayed presentation, protean manifestations
– Diagnosis delayed: AFB culture/PCR required
– Treatment of invasive/disseminated difficult
• Multidrug medical therapy (3+ agents)
• Surgical removal of prosthetic devices

– Very high crude mortality rate (>=50%)

Summary: Hospital response
• Actively notify exposed patients via multiple
means including media outlets
• Consider all LivaNova 3T HCDs contaminated
– Culturing of HCDs of limited value
– Follow manufacturer’s disinfection instructions
– Decontamination approaches unreliable

• Most important means of risk mitigation is to
separate the HCD bioaerosol from the patient

Future directions
• Re-designed heater-cooler systems
• Greater infection control scrutiny of devices
– e.g. scopes, HCDs, ability to operate safely

• Improved diagnostics (e.g. NGS, other)
• Registry for M. chimaera cases
– Diagnosis, treatment, outcomes

